Experts are rapidly focused on retatrutide, a innovative medication developed by Eli Lilly, as a possible advance in body management. Unlike many earlier approaches, retatrutide is a twin-action receptor targeting simultaneously GLP-1 and GIP, hormones that affect appetite and blood glucose regu